LAPIX’s pipeline of therapeutics is robust and game changing. LPX-TI641 will be in Phase I trials June 2023. LPX-TIIBD will follow with clinical trials starting June 2024 with the immunotherapy asset anticipated starting clinical trials 2H 2024.